{"id":"NCT01964716","sponsor":"Pfizer","briefTitle":"13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.","officialTitle":"A Phase 3, Randomized, Open-label Trial To Evaluate The Safety, Tolerability And Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials Given With Routine Pediatric Vaccinations In Healthy Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01","primaryCompletion":"2014-09","completion":"2014-09","firstPosted":"2013-10-17","resultsPosted":"2015-03-13","lastUpdate":"2015-03-13"},"enrollment":500,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Vaccines"],"interventions":[{"type":"BIOLOGICAL","name":"13-valent pneumococcal conjugate vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"13-valent pneumococcal conjugate vaccine","otherNames":[]}],"arms":[{"label":"Multidose Vial Group","type":"EXPERIMENTAL"},{"label":"Single-Dose Syringe Group","type":"ACTIVE_COMPARATOR"}],"summary":"This study will compare the immune responses of the infants who have been given 13vPnC in the mutidose vial formulation to the immune reponses of the infants who have been given 13vPnC in the single-dose syringe formulation.\n\nIt will also evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in all infants who are vaccinated.","primaryOutcome":{"measure":"Percentage of Participants Achieving a Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal To (>=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After the Infant Series for Each Vaccine Group","timeFrame":"1 month after the infant series","effectByArm":[{"arm":"13vPnC Multi-dose Vial (MDV)","deltaMin":99.2,"sd":null},{"arm":"13vPnC Single-Dose Syringe (SDS)","deltaMin":100,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"42 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":2,"countries":["The Gambia"]},"refs":{"pmids":["28479175"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4671001&StudyName=13vPnC%20Multidose%20Vial%20Safety%2C%20Tolerability%20and%20Immunogenicity%20Study%20in%20Healthy%20Infants."]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":250},"commonTop":["Irritability: Any","Irritability: Mild","Tenderness: Any","Tenderness: Mild","Decreased appetite: Any"]}}